Favorable influence of subclinical hypothyroidism on the functional outcomes in stroke patients

Jang Hyun Baek, Pil Wook Chung, Yong Bum Kim, Heui Soo Moon, Bum Chun Suh, Dong Kwan Jin, Byung Moon Kim, Eun Jung Rhee, Yong Taek Lee, Kwang Yeol Park

Research output: Contribution to journalArticle

22 Citations (Scopus)

Abstract

Subclinical hypothyroidism (SCH) is thought to have an influence on stroke outcomes. However, few reports demonstrate a favorable relationship between the two. We evaluated this association in acute ischemic stroke. From Jan 2005 to Jun 2008, 756 acute ischemic stroke patients were recruited within seven days of onset. The patients with overt hypothyroidism/hyperthyroidism or other medical conditions that may affect thyroid function were excluded. Thyroid stimulating hormone (TSH) and free thyroxine (FT4) levels were measured within two days. Patients were divided into two groups: the SCH group (TSH > 5.0 μU/mL and normal FT4 levels) and the control group. Stroke outcomes were assessed using two different criteria. In the first outcome model, favorable outcomes [I] were simply defined by modified Rankin Scale (mRS) scores (≦ 1), while the favorable outcomes [II] were defined as follows: a) a mRS score of 0, if the baseline National Institute of Health Stroke Scale (NIHSS) scores were < 8, b) a mRS score of 0 or 1, if the NIHSS scores were 8-14, c) a mRS score 0-2, if the NIHSS scores were >14. The changes in mRS scores and the proportion of patients with favorable outcomes [I] or [II] at the 30th and 90 th day were compared between the two patient groups. Of the 756 patients, 31 (4.1%) were patients with SCH. More patients from the SCH group showed improvement in NIHSS scores on the 30th day compared to the control group (48.4% vs. 25.3%, p=0.006). In addition, the proportion of patients who exhibited favorable outcomes [I] was significantly higher in the SCH group on the 90th day (74.2% vs. 55.3%, p=0.027) and that trend was seen as early as the 30th day (p=0.102). Similarly, the proportion of the patients with favorable outcomes [II] was significantly greater in the SCH group both on the 30th (29.0% vs. 14.6%, p=0.039) and 90th day (58.0% vs. 31.0%, p=0.003). We found that acute ischemic stroke patients with SCH at admission were more likely to show favorable functional outcomes than those without SCH. We can suggest preconditioning before the stroke combined with a reduced response to stress as a possible protective mechanism.

Original languageEnglish
Pages (from-to)23-29
Number of pages7
JournalEndocrine Journal
Volume57
Issue number1
DOIs
Publication statusPublished - 2010 Feb 11

Fingerprint

Hypothyroidism
Stroke
National Institutes of Health (U.S.)
Thyrotropin
Control Groups
Hyperthyroidism
Thyroxine
Thyroid Gland

All Science Journal Classification (ASJC) codes

  • Endocrinology, Diabetes and Metabolism
  • Endocrinology

Cite this

Baek, J. H., Chung, P. W., Kim, Y. B., Moon, H. S., Suh, B. C., Jin, D. K., ... Park, K. Y. (2010). Favorable influence of subclinical hypothyroidism on the functional outcomes in stroke patients. Endocrine Journal, 57(1), 23-29. https://doi.org/10.1507/endocrj.K09E-206
Baek, Jang Hyun ; Chung, Pil Wook ; Kim, Yong Bum ; Moon, Heui Soo ; Suh, Bum Chun ; Jin, Dong Kwan ; Kim, Byung Moon ; Rhee, Eun Jung ; Lee, Yong Taek ; Park, Kwang Yeol. / Favorable influence of subclinical hypothyroidism on the functional outcomes in stroke patients. In: Endocrine Journal. 2010 ; Vol. 57, No. 1. pp. 23-29.
@article{6b9a2f0fd44343a5ad2f4ef071dbe2cf,
title = "Favorable influence of subclinical hypothyroidism on the functional outcomes in stroke patients",
abstract = "Subclinical hypothyroidism (SCH) is thought to have an influence on stroke outcomes. However, few reports demonstrate a favorable relationship between the two. We evaluated this association in acute ischemic stroke. From Jan 2005 to Jun 2008, 756 acute ischemic stroke patients were recruited within seven days of onset. The patients with overt hypothyroidism/hyperthyroidism or other medical conditions that may affect thyroid function were excluded. Thyroid stimulating hormone (TSH) and free thyroxine (FT4) levels were measured within two days. Patients were divided into two groups: the SCH group (TSH > 5.0 μU/mL and normal FT4 levels) and the control group. Stroke outcomes were assessed using two different criteria. In the first outcome model, favorable outcomes [I] were simply defined by modified Rankin Scale (mRS) scores (≦ 1), while the favorable outcomes [II] were defined as follows: a) a mRS score of 0, if the baseline National Institute of Health Stroke Scale (NIHSS) scores were < 8, b) a mRS score of 0 or 1, if the NIHSS scores were 8-14, c) a mRS score 0-2, if the NIHSS scores were >14. The changes in mRS scores and the proportion of patients with favorable outcomes [I] or [II] at the 30th and 90 th day were compared between the two patient groups. Of the 756 patients, 31 (4.1{\%}) were patients with SCH. More patients from the SCH group showed improvement in NIHSS scores on the 30th day compared to the control group (48.4{\%} vs. 25.3{\%}, p=0.006). In addition, the proportion of patients who exhibited favorable outcomes [I] was significantly higher in the SCH group on the 90th day (74.2{\%} vs. 55.3{\%}, p=0.027) and that trend was seen as early as the 30th day (p=0.102). Similarly, the proportion of the patients with favorable outcomes [II] was significantly greater in the SCH group both on the 30th (29.0{\%} vs. 14.6{\%}, p=0.039) and 90th day (58.0{\%} vs. 31.0{\%}, p=0.003). We found that acute ischemic stroke patients with SCH at admission were more likely to show favorable functional outcomes than those without SCH. We can suggest preconditioning before the stroke combined with a reduced response to stress as a possible protective mechanism.",
author = "Baek, {Jang Hyun} and Chung, {Pil Wook} and Kim, {Yong Bum} and Moon, {Heui Soo} and Suh, {Bum Chun} and Jin, {Dong Kwan} and Kim, {Byung Moon} and Rhee, {Eun Jung} and Lee, {Yong Taek} and Park, {Kwang Yeol}",
year = "2010",
month = "2",
day = "11",
doi = "10.1507/endocrj.K09E-206",
language = "English",
volume = "57",
pages = "23--29",
journal = "Endocrine Journal",
issn = "0918-8959",
publisher = "Japan Endocrine Society",
number = "1",

}

Baek, JH, Chung, PW, Kim, YB, Moon, HS, Suh, BC, Jin, DK, Kim, BM, Rhee, EJ, Lee, YT & Park, KY 2010, 'Favorable influence of subclinical hypothyroidism on the functional outcomes in stroke patients', Endocrine Journal, vol. 57, no. 1, pp. 23-29. https://doi.org/10.1507/endocrj.K09E-206

Favorable influence of subclinical hypothyroidism on the functional outcomes in stroke patients. / Baek, Jang Hyun; Chung, Pil Wook; Kim, Yong Bum; Moon, Heui Soo; Suh, Bum Chun; Jin, Dong Kwan; Kim, Byung Moon; Rhee, Eun Jung; Lee, Yong Taek; Park, Kwang Yeol.

In: Endocrine Journal, Vol. 57, No. 1, 11.02.2010, p. 23-29.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Favorable influence of subclinical hypothyroidism on the functional outcomes in stroke patients

AU - Baek, Jang Hyun

AU - Chung, Pil Wook

AU - Kim, Yong Bum

AU - Moon, Heui Soo

AU - Suh, Bum Chun

AU - Jin, Dong Kwan

AU - Kim, Byung Moon

AU - Rhee, Eun Jung

AU - Lee, Yong Taek

AU - Park, Kwang Yeol

PY - 2010/2/11

Y1 - 2010/2/11

N2 - Subclinical hypothyroidism (SCH) is thought to have an influence on stroke outcomes. However, few reports demonstrate a favorable relationship between the two. We evaluated this association in acute ischemic stroke. From Jan 2005 to Jun 2008, 756 acute ischemic stroke patients were recruited within seven days of onset. The patients with overt hypothyroidism/hyperthyroidism or other medical conditions that may affect thyroid function were excluded. Thyroid stimulating hormone (TSH) and free thyroxine (FT4) levels were measured within two days. Patients were divided into two groups: the SCH group (TSH > 5.0 μU/mL and normal FT4 levels) and the control group. Stroke outcomes were assessed using two different criteria. In the first outcome model, favorable outcomes [I] were simply defined by modified Rankin Scale (mRS) scores (≦ 1), while the favorable outcomes [II] were defined as follows: a) a mRS score of 0, if the baseline National Institute of Health Stroke Scale (NIHSS) scores were < 8, b) a mRS score of 0 or 1, if the NIHSS scores were 8-14, c) a mRS score 0-2, if the NIHSS scores were >14. The changes in mRS scores and the proportion of patients with favorable outcomes [I] or [II] at the 30th and 90 th day were compared between the two patient groups. Of the 756 patients, 31 (4.1%) were patients with SCH. More patients from the SCH group showed improvement in NIHSS scores on the 30th day compared to the control group (48.4% vs. 25.3%, p=0.006). In addition, the proportion of patients who exhibited favorable outcomes [I] was significantly higher in the SCH group on the 90th day (74.2% vs. 55.3%, p=0.027) and that trend was seen as early as the 30th day (p=0.102). Similarly, the proportion of the patients with favorable outcomes [II] was significantly greater in the SCH group both on the 30th (29.0% vs. 14.6%, p=0.039) and 90th day (58.0% vs. 31.0%, p=0.003). We found that acute ischemic stroke patients with SCH at admission were more likely to show favorable functional outcomes than those without SCH. We can suggest preconditioning before the stroke combined with a reduced response to stress as a possible protective mechanism.

AB - Subclinical hypothyroidism (SCH) is thought to have an influence on stroke outcomes. However, few reports demonstrate a favorable relationship between the two. We evaluated this association in acute ischemic stroke. From Jan 2005 to Jun 2008, 756 acute ischemic stroke patients were recruited within seven days of onset. The patients with overt hypothyroidism/hyperthyroidism or other medical conditions that may affect thyroid function were excluded. Thyroid stimulating hormone (TSH) and free thyroxine (FT4) levels were measured within two days. Patients were divided into two groups: the SCH group (TSH > 5.0 μU/mL and normal FT4 levels) and the control group. Stroke outcomes were assessed using two different criteria. In the first outcome model, favorable outcomes [I] were simply defined by modified Rankin Scale (mRS) scores (≦ 1), while the favorable outcomes [II] were defined as follows: a) a mRS score of 0, if the baseline National Institute of Health Stroke Scale (NIHSS) scores were < 8, b) a mRS score of 0 or 1, if the NIHSS scores were 8-14, c) a mRS score 0-2, if the NIHSS scores were >14. The changes in mRS scores and the proportion of patients with favorable outcomes [I] or [II] at the 30th and 90 th day were compared between the two patient groups. Of the 756 patients, 31 (4.1%) were patients with SCH. More patients from the SCH group showed improvement in NIHSS scores on the 30th day compared to the control group (48.4% vs. 25.3%, p=0.006). In addition, the proportion of patients who exhibited favorable outcomes [I] was significantly higher in the SCH group on the 90th day (74.2% vs. 55.3%, p=0.027) and that trend was seen as early as the 30th day (p=0.102). Similarly, the proportion of the patients with favorable outcomes [II] was significantly greater in the SCH group both on the 30th (29.0% vs. 14.6%, p=0.039) and 90th day (58.0% vs. 31.0%, p=0.003). We found that acute ischemic stroke patients with SCH at admission were more likely to show favorable functional outcomes than those without SCH. We can suggest preconditioning before the stroke combined with a reduced response to stress as a possible protective mechanism.

UR - http://www.scopus.com/inward/record.url?scp=76049130349&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=76049130349&partnerID=8YFLogxK

U2 - 10.1507/endocrj.K09E-206

DO - 10.1507/endocrj.K09E-206

M3 - Article

C2 - 19823001

AN - SCOPUS:76049130349

VL - 57

SP - 23

EP - 29

JO - Endocrine Journal

JF - Endocrine Journal

SN - 0918-8959

IS - 1

ER -